Login to Your Account



Financings NEWS

Chemotherapeutic developer Odonate Therapeutics Inc. extended the 2017 biopharma IPO window, offering 6.25 million common shares at $24 apiece to raise $150 million.

'We've got something pretty special here'

Michael Gilman keeps staring down retirement. The scientist and serial entrepreneur, late of Padlock Therapeutics Inc., which was sold last year to Bristol-Myers Squibb Co. for $600 million, has been splitting his time between Arrakis Therapeutics Inc., where he serves as CEO, and an Atlas Venture company focused on gene and cell therapy. 

LONDON – Allecra Therapeutics GmbH closed a €9 million (US$10.7 million) first tranche of a series C round, enabling it to fund phase III development of AAI-101 in the treatment of serious hospital-acquired gram-negative infections.

More Financings Headlines

Cast Your Vote

Should there be restrictions on the use of gene-editing technology?: